149 results
Page 4 of 8
8-K
EX-99.1
oo4va13o
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
wz82f3dg8edm96
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.1
vewzi3no
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
5b2oe1pm
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
uf4i18
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.2
ekn72l4wfou14 5y
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
6dkab8wszqq
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
2zagsmwvayc0bnd
16 Sep 19
Entry into a Material Definitive Agreement
7:09am
8-K
EX-99.1
0gnvnkwl a1zu
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
fgfji i0g40
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
3byc3if14y
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
ofinmx
19 Jun 19
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
4:05pm
8-K
EX-99.1
sky9q8l
14 Jun 19
Other Events
7:33am
424B5
qxeep 1c59cin0ygbgqt
10 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
njmeou rfqfgfwhvggw
9 May 19
Results of Operations and Financial Condition
7:10am
PRE 14A
v4u94x3ndxe16v ykvn
2 Apr 19
Preliminary proxy
4:29pm